【目的】观察多西他赛联合奥沙利铂与替加氟方案治疗晚期胃癌的临床疗效和不良反应。【方法】32例均经病理组织学诊断为胃癌，初治病例18例，复治病例14例，每例均完成至少2个周期化疗。治疗方案：多西他赛75 mg／m2，d1，静滴2 h；奥...【目的】观察多西他赛联合奥沙利铂与替加氟方案治疗晚期胃癌的临床疗效和不良反应。【方法】32例均经病理组织学诊断为胃癌，初治病例18例，复治病例14例，每例均完成至少2个周期化疗。治疗方案：多西他赛75 mg／m2，d1，静滴2 h；奥沙利铂130 mg／m2，d2，静滴；替加氟800 mg／m2，微量泵持续静滴，维持22 h ，d2～3，21 d为一周期。【结果】32例患者总有效率为17例（53．1％），中位肿瘤进展时间（T T P ）13个月，不良反应为白细胞下降24例（75．0％），恶心，呕吐21例（65．6％），周围神经毒性13例（40．6％），脱发10例（31．3％）。【结论】多西他赛联合奥沙利铂与替加氟方案治疗晚期胃癌临床疗效好，不良反应可耐受。展开更多
With its novel chemical structure, artemisinin is an antimalarial component isolated from the traditional Chinese medicine qinghao(Artemisia annua L.). Nowadays, artemisinin and its derivatives are used compatibly wit...With its novel chemical structure, artemisinin is an antimalarial component isolated from the traditional Chinese medicine qinghao(Artemisia annua L.). Nowadays, artemisinin and its derivatives are used compatibly with new synthesized chemical antimalarial compounds to create artemisinin-based combination therapies(ACTs). These have become the first choice in treating malaria p.f. all over the world, providing an effective solution for the global challenge of curing drug-resistant malaria. Among the five ACTs recommended by the WHO, two were initiated in China and are used as the first-line treatment of falciparum malaria in all malaria endemic areas. As the use of artemisinin-based compound drugs have made such significant contributions to rolling back malaria, regarded as one of the great achievements globally in public health of the early twenty-first century, Tu Youyou, one of the most important researchers in the discovery of artemisinin, was made the first Nobel Prize laureate in Physiology or Medicine from the Chinese mainland. Artemisinin was discovered in a special social and cultural context through a combination of the exploration of traditional Chinese medical literature with the modern research approach of pharmaceutical sciences. This(Project 523) is a typical case of goal-oriented research leading to scientific advance, and the result of scientific research driven by the national needs.展开更多
文摘【目的】观察多西他赛联合奥沙利铂与替加氟方案治疗晚期胃癌的临床疗效和不良反应。【方法】32例均经病理组织学诊断为胃癌，初治病例18例，复治病例14例，每例均完成至少2个周期化疗。治疗方案：多西他赛75 mg／m2，d1，静滴2 h；奥沙利铂130 mg／m2，d2，静滴；替加氟800 mg／m2，微量泵持续静滴，维持22 h ，d2～3，21 d为一周期。【结果】32例患者总有效率为17例（53．1％），中位肿瘤进展时间（T T P ）13个月，不良反应为白细胞下降24例（75．0％），恶心，呕吐21例（65．6％），周围神经毒性13例（40．6％），脱发10例（31．3％）。【结论】多西他赛联合奥沙利铂与替加氟方案治疗晚期胃癌临床疗效好，不良反应可耐受。
文摘With its novel chemical structure, artemisinin is an antimalarial component isolated from the traditional Chinese medicine qinghao(Artemisia annua L.). Nowadays, artemisinin and its derivatives are used compatibly with new synthesized chemical antimalarial compounds to create artemisinin-based combination therapies(ACTs). These have become the first choice in treating malaria p.f. all over the world, providing an effective solution for the global challenge of curing drug-resistant malaria. Among the five ACTs recommended by the WHO, two were initiated in China and are used as the first-line treatment of falciparum malaria in all malaria endemic areas. As the use of artemisinin-based compound drugs have made such significant contributions to rolling back malaria, regarded as one of the great achievements globally in public health of the early twenty-first century, Tu Youyou, one of the most important researchers in the discovery of artemisinin, was made the first Nobel Prize laureate in Physiology or Medicine from the Chinese mainland. Artemisinin was discovered in a special social and cultural context through a combination of the exploration of traditional Chinese medical literature with the modern research approach of pharmaceutical sciences. This(Project 523) is a typical case of goal-oriented research leading to scientific advance, and the result of scientific research driven by the national needs.
